Vera’s newly approved IgA nephropathy drug supports kidney function, like Otsuka’s Voyxact
In June, Otsuka Pharmaceuticals touted data suggesting its IgA nephropathy drug Voyxact could slow the decline of kidney function in patients—a unique benefit, analysts said at the time. Now, Vera Therapeutics seems to have taken that distinguishing …